NCT01322386View on ClinicalTrials.gov

Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

January 31, 2012

Conditions
Primary Sclerosing CholangitisBiliary Atresia
Interventions
DRUG

Vancomycin

Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.

All Listed Sponsors
lead

Stanford University

OTHER

NCT01322386 - Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | Biotech Hunter | Biotech Hunter